Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year.
Sanofi said its patient assistance programs limit out-of-pockets expenses for most insured patients to $15 a month, while uninsured people could pay $35 a month, but did not comment on whether it would drop to a $25 price following Lilly.BMO analyst Evan Seigerman said he expects Novo will have to match Lilly's pricing.
The list price for Lispro, a cheaper version of its Humalog insulin, is currently $82.41 for 100 units/mL vials. A Humalog U-100 10 mL vial is $274.70, which will drop to $66.40, and a Humulin U-100 10 mL vial is $148.70. That will become $44.61.List prices for drugs often differ from what patients actually pay, including after insurance and other assistance programs.
These price cuts "should be the new standard in America," the CEO said, and he called on other companies and stakeholders "to meet us at this point."
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
'Brilliant PR Move': Advocates Skeptical as Eli Lilly Vows 70% Insulin Price Cut'Congress, not greedy corporations trying to redeem their tarnished reputations, should be leading the way on reforms that put patients ahead of pharmaceutical profits.'
Baca lebih lajut »
Eli Lilly to cut insulin prices by 70%, cap monthly costs at $35The price reductions for the life-saving medication come amid criticism that unaffordable insulin may constitute a human rights abuse.
Baca lebih lajut »
Eli Lilly to cut insulin prices by 70 percentPharmaceutical giant Eli Lilly is slashing prices of commonly prescribed insulin drugs by 70 percent while capping related out-of-pocket costs at $35 a month, a move that should help address long-standing concerns about the high cost of diabetes care.
Baca lebih lajut »
Under pressure, Eli Lilly cuts insulin prices 70%NEW: Eli Lilly is slashing the prices of its most-prescribed insulins amid pressure from consumers and the Biden administration. People with diabetes would see 70% reductions on its most common versions between now and the end of the year.
Baca lebih lajut »
Eli Lilly cuts insulin prices up to 70% amid pressure to slash costsEli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. MORE ⬇️
Baca lebih lajut »